Impacto de la auto - percepción de imagen corporal en sujetos con VIH y lipoatrofia facial.


Autoria(s): Lizarralde Lara, Monica; Acevedo Cubillos, Diana Andrea; Rivera-Largacha, Silvia; Restrepo-Espinosa, Maria Helena; González, Angela
Contribuinte(s)

Lizarralde Lara, Monica

Data(s)

06/12/2012

Resumo

La lipoatrofia facial es uno de los efectos secundarios que con más frecuencia se presenta y afecta la calidad de vida del paciente con VIH que recibe tratamiento antiretroviral. Metodología: Estudio observacional de corte transversal que involucró 126 sujetos, a quienes se aplicó una encuesta semi-estructurada para determinar cómo percibe el paciente que la lipoatrofia facial lo afecta en áreas afectiva, social, laboral y ocupacional; evaluar la percepción de la imagen corporal; caracterizar sociodemográficamente; determinar la prevalencia de lipoatrofia facial y establecer si hay diferencias de percepción de la imagen corporal según la caracterización sociodemográfica. Resultados: La Prevalencia de lipoatrofia facial fue del 57.1%. El grado de satisfacción en cuanto a apariencia física tuvo un promedio de 5.01±2.69. El 88.7% y 80.3% de los pacientes evaluados sintieron tristeza y frustración con su apariencia respectivamente. El 53.5% y el 42.9% informaron menos oportunidades laborales y educativas. La orientación sexual reportada con mayor frecuencia fue homosexualidad. No hubo diferencias estadísticamente significativas entre el grado de satisfacción de apariencia con aspectos sociodemográficos excepto en pacientes que recibieron apoyo psicológico. Conclusión: Primer estudio en el país que evalúa el impacto de la lipoatrofia facial en pacientes con VIH y tratamiento antiretroviral. Aunque la presencia de lipoatrofia facial sobre la cotidianidad no es estadísticamente significativa, si resulta trascendental pues existen porcentajes importantes de emociones y alteraciones psicológicas que afectan directamente a estos sujetos en las áreas afectiva, social, laboral y ocupacional. Se hace necesaria la realización de más estudios que permitan obtener mayor de evidencia.

Facial lipoatrophy is one of the side effects that most frequently occurs and affects the quality of life of patients with HIV receiving antiretroviral treatment. Methods: Cross-sectional observational study involving 126 subjects, who were surveyed semi-structured to determine how the patient perceives that it affects facial lipoatrophy in areas affective, social, labor and occupational evaluate the perception of body image ; characterize sociodemographically; determine the prevalence of facial lipoatrophy and whether there are differences in perception of body image according to sociodemographic. Results: The prevalence of facial lipoatrophy was 57.1%. The degree of satisfaction with physical appearance had an average of 5.01 ± 2.69. The 88.7% and 80.3% of patients tested felt sadness and frustration with their appearance respectively. The 53.5% and 42.9% reported fewer employment and educational opportunities. Sexual orientation was most frequently reported homosexuality. There were no statistically significant differences between the degree of satisfaction with sociodemographic appearance except in patients who received psychological support. Conclusion: First nationwide study that evaluates the impact of facial lipoatrophy in patients with HIV and antiretroviral treatment. Although the presence of facial lipoatrophy, on everyday is not statistically significant if there is momentous because significant percentages of emotions and psychological disorders that directly affect these subject areas in affective, social, labor and occupational. It is necessary to conduct more studies to obtain further evidence.

Formato

application/pdf

Identificador

http://repository.urosario.edu.co/handle/10336/4117

Idioma(s)

spa

Publicador

Facultad de Medicina

Direitos

info:eu-repo/semantics/openAccess

Fonte

instname:Universidad del Rosario

reponame:Repositorio Institucional EdocUR

García M. Evaluación de la calidad de vida en personas VIH positivas con lipodistrofia. Psicología y Salud (México). 2004; 14: 5-11.

Naini FB, Moss JP, Gill DS. The enigma of facial beauty: aesthetics, proportions, deformity, and controversy. Am J Orthod Dentofacial Orthop. 2006; 130: 277-82

Rumsey N, Clarke A, White P et al. Altered body image: appearance-related concerns of people with visible disfigurement. J Adv Nurs. 2004; 48: 443-53.

Bayer R. Historia de la estética. Editorial Manual Moderno; 2002.

Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000;10:546–550.

Blanch J, et al. Factors Associated with Severe Impact of Lipodystrophy on Quality of Life of Patients Infected with HIV-1. Clin Infect Dis 2004;38:1464-1470.

Guaraldi G, Orlando G, Murri R, et al. Quality of life and body image in the assessment of psychological impact of lipodystrophy: Validation of the Italian version of Assessment of Body Change and Distress questionnaire. Qual Life Res. 2006;15:173–178.

Martínez E. Actitud ante las alteraciones metabólicas y de distribución de la grasa corporal en pacientes infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral. Documento de Consenso de GESIDA y del Plan Nacional sobre el Sida 2002.

Papalia, D. Desarrollo humano. México: Editorial Mc Graw Hill, Interamericana, 2007.

Ministerio de Salud y Protección Social. Informe mundial de avances en la lucha contra el Sida. Colombia; 2012.

Secretaria distrital de salud dirección de salud pública. Situación de la epidemia por VIH en el distrito capital primer semestre de 2011. Bogota, Colombia; 2011.

Blanco F. Lipodistrophy Síndrome: Diagnostic, clinic and therapeutic aspects. AIDS Rev. 2001; 3: 98-105.

Chen D, Misra A, Garg A. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87: 4845-4856.

Rodríguez S. Anormalidades metabólicas en pacientes con infección por VIH. Rev Invest Clin 2004; 56: 193-208.

Lyon DE, Truban E. VIH-related lipodystrophy: a clinical syndrome with implications for nursing practice. J Assoc Nurses AIDS Care. 2000; 11: 36-42.

Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in VIH-infected adults: a case-control study. Lancet 2003; 361: 726-735.

James J, Carruthers A, Carruthers J. VIH-associated facial lipoatrophy. Dermatol Surg 2002; 28: 979-986.

Martinez E. Lipodystrophy Syndrome in Patients with VIH infection. Drug Safety 2001; 23: 157-66.

Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-VIH infected patients. J Med Assoc Thai 2004; 87: 605-611.

Robinson FP. VIH lipodystrophy syndrome: a primer. J Assoc Nurses AIDS Care 2004; 15: 15-29.

Tershakovec AM, Frank I, Rader D. VIH-related lipodystrophy and related factors. Atherosclerosis 2004; 174: 1-10.

McComsey, G. (2006). Reverse Transcriptase Inhibitors in HIV/AIDS Therapy; Infectous disease: Mitochondrial Toxicity and Lipodystrophy.281-302. Cleveland: Humana press.

Tungsiripat, M; McComsey,G. Pathogenesis and management of lipoatrophy. Current HIV/AIDS Reports, 2008, Volume 5, Number 2, Pages 55-63.

Nelson, L; Stewart, K. Experience in the treatment of HIV-associated Lipodystrophy. Journal of Plastic, Reconstructive & Aesthetic Surgery (2008) 61, 366-371.

Yang Y, Sitoh YY, Oo TN et al. Facial fat volume in VIH-infected patients with lipoatrophy. Antivir.Ther. 2005; 10: 575-81.

Funk E, Bressler FJ, Brissett AE. Contemporary surgical management of VIH-associated facial lipoatrophy. Otolaryngol.Head Neck Surg. 2006; 134: 1015-22.

Nelson, L; Stewart, K. Psychological morbidity and facial volume in HIV lipodystrophy: Quantification of treatment outcome. Journal of Plastic, Reconstructive & Aesthetic Surgery (2012) 65, 439 - 447.

Nolan D, Mallal S. Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sex Health 2005; 2: 153-63.

Burgoyne R, Collins E, Wagner C et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for VIH-positive adults. Qual.Life Res. 2005; 14: 981-90.

Dukers NH, Stolte IG, Albrecht N et al. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among VIH-infected homosexual men. AIDS 2001; 15: 812-3.

Jones D. VIH facial lipoatrophy: causes and treatment options. Dermatol.Surg. 2005; 31: 1519-29.

Paul Schilder. Imagen y apariencia del cuerpo humano, 1 edn. Barcelona: Paidós Ibérica, 1987.

Oette M, Juretzko P, Kroidl A et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in VIH-positive patients. AIDS Patient.Care STDS. 2002; 16: 413-7.

Doltó F. La imagen inconciente del cuerpo. Barcelona: Paidós Ibérica, 1986.

Varas Días, N, Toro J. My body, my stigma: Body interpretations in a sample of people living with VIH/AIDS in Puerto Rico. The Qualitative Report 2005; 10: 122-42.

Päivi, P. Body Image: A tripartite model for the use in dance movement therapy. American Journal of Dance Therapy 2003; 25: 39-55.

Zaidel DW, Aarde SM, Baig K. Appearance of symmetry, beauty, and health in human faces. Brain Cogn 2005; 57: 261-3.

Molassiotis A, Callaghan P, Twinn SF, Lam SW, Chung WY, Li CK. A pilot study of the effects of cognitive-behavioral group therapy and peer support/counseling in decreasing psychologic distress and improving quality of life in chinese patients with symptomatic HIV disease. AIDS Patient Care STDS 2002 Feb; 16 (2): 83-96.

Inoue Y, Yamazaki Y, Seki Y, Wakabayashi C, Kihara M. Sexual activities and social relationships of people with HIV in Japan. AIDS Care. 2004 Apr.16 (3):349-62.

Honn V J, Bornstein R A. Social support, neuropsychological performance, and depression in HIV infection. J Int Neuropsychol Soc 2002 Mar;8 (3): 436-47.

Morais A P. et al. Lipodystrophy syndrome associated with antiretroviral therapy in hiv patients: considerations for psychosocial aspects. Rev Latino-am Enfermagem 2007 set-oct; 15, (5).

Fleury E; Almeida A. Psychological well-being, coping and lipodystrophy in hiv/aids people. Psicologia em Estudo, Maringá 2008 Abr./jun 13, (2): 239-247.

Seron R; et al. Facial lipoatrophy: appearances are not deceiving. Journal of the association of nurses in aids care, 2009 may/june 20, (3): 169-175

TEME 0109 2012

Palavras-Chave #ENFERMEDADES DE LA PIEL - TRATAMIENTO #ENFERMOS DE SIDA - CUIDADO Y TRATAMIENTO #SIDA - TRATAMIENTO - EFECTOS ADVERSOS #SÍNDROME DE LIPODISTROFIA ASOCIADA A VIH #Human Immunodeficiency Virus #Facial lipoatrophy #Perception #Aesthetics #Body image
Tipo

info:eu-repo/semantics/bachelorThesis

info:eu-repo/semantics/acceptedVersion